This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log in
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Oct;101(4):727-728.
doi: 10.4269/ajtmh.19-0568.

Liposomal Amphotericin B Treatment and the Leishmaniases

Affiliations
Editorial

Liposomal Amphotericin B Treatment and the Leishmaniases

Jonathan Berman. Am J Trop Med Hyg. 2019 Oct.
No abstract available

PubMed Disclaimer

References

    1. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW, 2010. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 362: 504–512. - PubMed
    1. Sundar S, Singh A, Agrawal N, Chakravarty J, 2019. Effectiveness of single dose liposomal amphotericin B in visceral leishmaniasis in Bihar. Am J Trop Med Hyg 101: 795–798. - PMC - PubMed
    1. Singh OP, Hasker E, Boelaert M, Sundar S, 2016. Elimination of visceral leishmaniasis on the Indian subcontinent. Lancet Infect Dis 16: e304–e309. - PMC - PubMed
    1. Khalil EA, et al. 2014. Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial. PLoS Negl Trop Dis 8: e2613. - PMC - PubMed
    1. Davidson RN, et al. 1994. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med 87: 75–81. - PubMed

Publication types

MeSH terms

Full text links
Sheridan PubFactory full text link Sheridan PubFactory Free PMC article
Cite

AltStyle によって変換されたページ (->オリジナル) /